Organon (OGN) closed at $14.45 in the latest trading session, marking a -1.83% move from the prior day. This move was narrower than the S&P 500's daily loss of 4.84%. On the other hand, the Dow ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. If it goes ...

Organon (OGN) closed the latest trading day at $15.39, indicating a -1.35% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.08%. Elsewhere ...